Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
LEXINGTON, Mass., March 28, 2017 -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced that John McDonough, president and chief executive officer, is scheduled to attend and present at the Needham Healthcare Conference on Wednesday, April 5, 2017 at 11:20am ET at the Westin New York Grand Central Hotel in New York City.
A live, listen-only webcast of the presentation may be accessed by visiting the Events & Presentations section of the Company’s website at www.t2biosystems.com under Investors. A replay of the webcast will be available shortly after the conclusion of the presentation and will be archived on the Company's website for 90 days following the presentation.
About T2 Biosystems
T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With the FDA-cleared T2Dx® Instrument and T2Candida® Panel targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods. For more information, please visit www.t2biosystems.com.
Media Contact: Matthew McKillip, T2 Biosystems [email protected] 518-577-3466 Investor Contact: Tucker Elcock, Teneo Strategy [email protected] 212-886-9319
